CRIS Current Research Information System

ROSTI, GIANANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.267
AS - Asia 7.751
EU - Europa 6.366
SA - Sud America 482
AF - Africa 466
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 6
Totale 24.359
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.179
VN - Vietnam 2.114
SG - Singapore 2.060
CN - Cina 1.931
GB - Regno Unito 1.890
SE - Svezia 790
DE - Germania 773
IT - Italia 773
HK - Hong Kong 469
FR - Francia 411
IN - India 390
NL - Olanda 380
RU - Federazione Russa 352
BR - Brasile 341
UA - Ucraina 255
IE - Irlanda 219
JP - Giappone 190
ZA - Sudafrica 149
EE - Estonia 123
KR - Corea 116
TG - Togo 109
FI - Finlandia 88
CI - Costa d'Avorio 80
JO - Giordania 75
BG - Bulgaria 64
CH - Svizzera 63
CA - Canada 57
AR - Argentina 52
ID - Indonesia 47
PH - Filippine 45
NG - Nigeria 42
BD - Bangladesh 39
TH - Thailandia 37
TR - Turchia 36
BE - Belgio 35
IQ - Iraq 32
AT - Austria 30
EC - Ecuador 29
TW - Taiwan 28
PL - Polonia 26
GR - Grecia 23
IR - Iran 23
SC - Seychelles 23
AU - Australia 19
ES - Italia 19
MX - Messico 19
CL - Cile 18
SA - Arabia Saudita 18
MY - Malesia 15
PK - Pakistan 14
RO - Romania 14
MA - Marocco 13
AE - Emirati Arabi Uniti 11
CO - Colombia 11
LB - Libano 11
PY - Paraguay 11
UZ - Uzbekistan 11
VE - Venezuela 10
EG - Egitto 9
ET - Etiopia 9
IL - Israele 9
KE - Kenya 9
TN - Tunisia 8
CZ - Repubblica Ceca 6
NP - Nepal 6
BY - Bielorussia 5
PS - Palestinian Territory 5
HN - Honduras 4
LT - Lituania 4
PE - Perù 4
UG - Uganda 4
EU - Europa 3
GE - Georgia 3
LY - Libia 3
NO - Norvegia 3
PT - Portogallo 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
UY - Uruguay 3
AL - Albania 2
AZ - Azerbaigian 2
BO - Bolivia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
JM - Giamaica 2
KZ - Kazakistan 2
MV - Maldive 2
NZ - Nuova Zelanda 2
OM - Oman 2
SY - Repubblica araba siriana 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
CR - Costa Rica 1
CY - Cipro 1
GM - Gambi 1
HR - Croazia 1
IM - Isola di Man 1
Totale 24.342
Salva come PNG Salva come JPEG
Città #
Southend 1.692
Singapore 1.411
Fairfield 1.032
Ashburn 924
Chandler 782
Woodbridge 543
Houston 505
Wilmington 489
Seattle 477
Hong Kong 438
San Jose 435
Ho Chi Minh City 417
Dong Ket 406
Hanoi 365
Cambridge 347
Princeton 327
Ann Arbor 317
Beijing 297
Hefei 225
Dublin 218
Boardman 210
Santa Clara 174
Nanjing 168
Lauterbourg 162
Tokyo 162
Westminster 145
Bologna 131
Padova 131
Jacksonville 130
Dallas 110
Lomé 109
Los Angeles 101
New York 99
Berlin 93
Seoul 90
Helsinki 82
Abidjan 79
Buffalo 75
Saint Petersburg 73
Amman 72
Jinan 70
Shenyang 65
Sofia 63
Turin 62
Changsha 58
Milan 57
Haiphong 56
Bern 55
Da Nang 55
San Diego 54
Nanchang 53
Hebei 51
Falls Church 45
Munich 44
Frankfurt am Main 43
Guangzhou 43
Redondo Beach 43
Jiaxing 42
São Paulo 41
Abeokuta 38
Tianjin 35
Brussels 34
Shanghai 34
Bremen 32
Medford 32
Redmond 32
Zhengzhou 31
Falkenstein 29
Mülheim 27
Jakarta 26
Norwalk 26
Dearborn 25
Florence 25
London 25
Orem 25
Bengaluru 24
Des Moines 24
Warsaw 24
Nuremberg 23
Phoenix 23
Rome 23
Chengdu 22
Council Bluffs 22
Hangzhou 22
Hải Dương 21
Biên Hòa 20
Haikou 20
Wuhan 19
Can Tho 18
Taizhou 18
Toronto 17
Washington 17
Chicago 16
Bangkok 15
Brooklyn 15
Mahé 15
Redwood City 15
Yubileyny 15
Baghdad 14
Mountain View 14
Totale 15.995
Salva come PNG Salva come JPEG
Nome #
Consensus conference on the management of tumor lysis syndrome. 440
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 385
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 351
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 299
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 289
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 283
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukaemia: a European LeukemiaNet study 279
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 273
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 265
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 252
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 251
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib 242
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 239
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 233
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 228
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 226
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 224
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 219
A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia 218
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 214
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 205
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 201
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: Effects on response rate, toxicity and outcome 195
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 194
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. 192
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA 189
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients 188
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis 187
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 186
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response 186
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview 186
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 183
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells 182
A review of the European LeukemiaNet recommendations for the management of CML 179
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia 179
Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. 176
Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience 175
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 175
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 174
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 173
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia 173
Charlson comorbidity index and adult comorbidity evaluation-27 might predict compliance and development of pleural effusions in elderly chronic myeloid leukemia patients treated with dasatinib after resistance/intolerance to imatinib. 172
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 171
In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study. 169
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 167
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 166
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 166
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 166
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia 165
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 164
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL 163
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 162
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study 161
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison. 159
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 159
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis 159
Leucemia mieloide cronica: terapia molecolare 158
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 158
Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC50? 157
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia 157
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants 157
Digital PCR (dPCR) Overcomes the Limitations in Detection and in Quantification of Quantitative PCR (qPCR) and Reveals Different Levels of BCR-ABL1 Copies/µl Among the Chronic Myeloid Leukemia (CML) Patients Achieving Major (MR3.0) or DEEP (MR4.0, MR4.5 and MR5.0) Molecular Response with Tyrosin Kynase Inhibitors (TKIs) 157
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 157
Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. 157
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival 156
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 156
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 153
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy 152
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors 151
High Sensitivity Mutation Monitoring and Clonal Analysis by Ultra-Deep Amplicon Sequencing Uncover the Complexity of BCR-ABL Mutation Status in Philadelphia+ Patients Treated with Tyrosine Kinase Inhibitors 150
Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type 150
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study 150
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 149
Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 149
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. 148
Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. 147
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia 145
INTERMITTENT IMATINIB (INTERIM) TREATMENT IN PH+-CML ELDERLY PATIENTS IN STABLE COMPLETE CYTOGENETIC RESPONSE 145
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib 145
Tyrosine kinase inhibitors in chronic myeloid leukaemia: Which, when, for whom? 143
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series 141
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 141
Diagnosis and classification of the risk 140
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 140
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights 138
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors 138
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 138
Resistance to second-line tyrosine kinase inhibitor treatment in imatinib-resistant Philadelphia-positive leukemia patients can be anticipated by ultra-deep sequencing of the BCR-ABL kinase domain using Roche 454 technology 138
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. 137
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 137
Explaining the in vitro and in vivo differences in leukemia therapy. 136
Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance 136
The long-term durability of cytogenetic response in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up 134
High Sensitivity Mutation Screening and Clonal Analysis Allowed by Ultra-Deep Amplicon Sequencing Uncover the Complexity of Bcr-Abl Mutation Status in Patients Treated with Tyrosine Kinase Inhibitors 134
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. 132
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib 131
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. 130
Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies 129
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib 126
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. 126
Totale 18.106
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.915
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.915
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021990 0 0 0 0 0 0 0 0 0 95 177 718
2021/20222.827 342 88 200 257 269 171 53 177 110 193 463 504
2022/20233.104 378 494 174 378 221 224 124 170 505 64 247 125
2023/2024886 47 134 54 89 71 217 49 50 22 51 65 37
2024/20253.241 95 505 289 213 382 160 231 81 37 441 129 678
2025/20266.604 528 650 781 477 846 403 669 342 1.443 465 0 0
Totale 24.838